首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1426879

全球抗真菌治療市場：~2032 年

Antifungal Treatment Market Research Report Forecast to 2032

出版日期: 2024年02月10日 | 出版商:

Market Research Future | 英文 156 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

在預測期內，抗真菌治療市場規模預計將以 3.89% 的複合年增長率增長。寄生蟲感染的增加和□□免疫感染的傳播是市場成長的主要貢獻者。

按地區劃分，北美將佔據最大份額，到 2022 年將超過 40%。患有傳染病的人數增加是導致市場佔有率擴大的因素之一。

本報告調查了全球抗真菌治療藥物市場，提供了市場的定義和概述，分析了市場增長的各種影響因素、市場規模的趨勢和預測、各個細分市場和地區的細分，總結了競爭環境，主要公司簡介等

Contagious diseases incorporate both foundational and shallow contaminations, including contaminations of the skin, eye, mouth, and vagina. Antifungal items with fungicidal movement are for the most part used to treat a wide cluster of illnesses, like competitor's foot, ringworm, and parasitic meningitis, brought about by contagious specialists.

Also, there are a few items accessible related with various courses of organization on the market for the treatment of contagious diseases, like oral and intravenous prescriptions, creams, splashes, shampoos, arrangements, pessaries, and infusions. Moreover, expanding dispatches of imaginative items is further fueling the development of the market. For example, in May 2022, Bayer AG (Germany) sent off a better than ever Canesten antifungal treatment arrangement in India. The product offering, which is accessible in powder and cream structures, has against parasitic properties that guide in the counteraction and treatment of skin contaminations. The antifungal cream gives alleviation from contamination, and the gentle steroid cream lessens the irritation because of disease.

Thus, the high accessibility of various courses of organization and the rising predominance of various sorts of contagious contaminations are encouraging market development.

Market Segmentation

The Antifungal Treatment Market is divided into drug classes, such as azoles, echinocandins, polyenes, allylamines, pyrimidines, and others.

Oral, topical, and parenteral are the categories into which the market is divided based on the mode of administration.

Dermatophytosis, aspergillosis, candidiasis, invasive candidiasis, vulvovaginal candidiasis, mouth/throat/esophageal candidiasis, and others are the segments of the market based on the indication.

The Antifungal Treatment Market is divided into categories based on pathogens, including zygomycetes, trichophyton, aspergillus, cryptococcus, and coccidioides immitis. Clinics for dermatology, hospitals & clinics, and other categories make up the end user market.

Regional Analysis

North America represented the biggest market portion of more than 40% in 2022 is attributable to different variables and one of them is expanding number of individuals with contagious contaminations. Also, market players are shaping methodologies to disseminate and sell antifungal medication in the US.

The Europe against contagious contamination market development is driven by significantly obtrusive parasitic diseases, which have been emphatically expanding since the last 10 years in the European nations. Also, patients with hematologic malignancies and hematopoietic cell relocate beneficiaries (HCT) are found to get obtrusive parasitic contaminations in the European populace.

The Asia-Pacific enemy of parasitic treatment market is the quickest developing region during the forecast time frame attributable to expanding contagious disease cases in Asian nations. In 2020, the Worldwide Activity for Parasitic Diseases (GAFFI) and Fudan College (Shanghai) assessed that 1,000,000 individuals experience the ill effects of obtrusive aspergillosis in China every year.

Major Players

Key Companies in the Antifungal Treatment Market includes Pfizer Inc (US), Johnson & Johnson Services, Inc (US), Bayer AG (Germany), Novartis AG (Switzerland), Abbott Laboraotories, Inc. (US), Merck KGaA (Germany), Gilead Sciences, Inc (US), Cipla, Inc. (India), Sanofi S.A. (France), and GlaxoSmithKline Plc (UK).

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 INCREASING INCIDENTS OF FUNGAL INFECTIONS
- 4.2.2 INCREASING PREVALENCE OF IMMUNOLOGICAL DISEASES
- 4.2.3 AVAILABILITY OF A WIDE RANGE OF PRODUCTS
4.3 RESTRAINTS
- 4.3.1 SIDE-EFFECTS OF TREATMENT
4.4 OPPORTUNITIES
- 4.4.1 DEVELOPMENT OF NEW DRUGS

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D & DESIGNING
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION & SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL ANTI-FUNGAL TREATMENT MARKET
- 5.3.1 IMPACT ON MAKET GROWTH
- 5.3.2 IMPACT ON SUPPLY CHAIN
- 5.3.3 IMPACT ON DIAGNOSTICS AND TESTING
- 5.3.4 CHANGES IN HEALTHCARE PRIORITIES
- 5.3.5 IMPACT ON CLINICAL TRIALS

6 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY DRUG CLASS

6.1 OVERVIEW
6.2 AZOLES
6.3 ECHINOCANDINS
6.4 POLYENES
6.5 ALLYLAMINES
6.6 PYRIMIDINES
6.7 OTHERS

7 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

7.1 OVERVIEW
7.2 ORAL
7.3 TOPICAL
7.4 PARENTERAL

8 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY INDICATION

8.1 OVERVIEW
8.2 DERMATOPHYTOSIS
8.3 ASPERGILLOSIS
8.4 CANDIDIASIS.
8.5 INVASIVE CANDIDIASIS.
8.6 VULVOVAGINAL CANDIDIASIS
8.7 MOUTH/THROAT/ESOPHAGEAL CANDIDIASIS
8.8 OTHERS

9 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY PATHOGENS

9.1 OVERVIEW
9.2 CANDIDA
9.3 ASPERGILLUS
9.4 CRYPTOCOCCUS
9.5 COCCIDIOIDES IMMITIS.
9.6 ZYGOMYCETES
9.7 TRICHOPHYTON
9.8 OTHERS

10 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY END USER

10.1 OVERVIEW
10.2 HOSPITAL AND CLINICS
10.3 DERMATOLOGICAL CLINICS
10.4 OTHERS

11 GLOBAL ANTI-FUNGAL TREATMENT MARKET, BY REGION

11.1 OVERVIEW
11.2 NORTH AMERICA
- 11.2.1 US
- 11.2.2 CANADA
11.3 EUROPE
- 11.3.1 GERMANY
- 11.3.2 FRANCE
- 11.3.3 UK
- 11.3.4 ITALY
- 11.3.5 SPAIN
- 11.3.6 SWITZERLAND
- 11.3.7 REST OF EUROPE
11.4 ASIA-PACIFIC
- 11.4.1 CHINA
- 11.4.2 INDIA
- 11.4.3 JAPAN
- 11.4.4 SOUTH KOREA
- 11.4.5 AUSTRALIA
- 11.4.6 REST OF ASIA-PACIFIC
11.5 REST OF THE WORLD
- 11.5.1 MIDDLE EAST
- 11.5.2 AFRICA
- 11.5.3 LATIN AMERICA

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW
12.2 COMPETITIVE BENCHMARKING
12.3 MAJOR GROWTH STRATEGY IN THE ANTI-FUNGAL TREATMENT MARKET
12.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE ANTI-FUNGAL TREATMENT MARKET
12.5 KEY DEVELOPMENT ANALYSIS
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 12.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
- 12.6.2 ACQUISITION
- 12.6.3 AGREEMENT
- 12.6.4 PARTNERSHIP
- 12.6.5 EXPANSION
12.7 MAJOR PLAYERS FINANCIAL
- 12.7.1 SALES (USD BILLION), 2022
- 12.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD BILLION), 2022

13 COMPANY PROFILES

13.1 PFIZER INC
- 13.1.1 COMPANY OVERVIEW
- 13.1.2 FINANCIAL OVERVIEW
- 13.1.3 PRODUCTS OFFERED
- 13.1.4 KEY DEVELOPMENTS
- 13.1.5 SWOT ANALYSIS
- 13.1.6 KEY STRATEGIES
13.2 MERCK KGAA
- 13.2.1 COMPANY OVERVIEW
- 13.2.2 FINANCIAL OVERVIEW
- 13.2.3 PRODUCTS OFFERED
- 13.2.4 KEY DEVELOPMENTS
- 13.2.5 SWOT ANALYSIS
- 13.2.6 KEY STRATEGIES
13.3 GILEAD SCIENCES, INC
- 13.3.1 COMPANY OVERVIEWS
- 13.3.2 FINANCIAL OVERVIEW
- 13.3.3 PRODUCTS OFFERED
- 13.3.4 KEY DEVELOPMENTS
- 13.3.5 KEY STRATEGIES
13.4 BAYER AG
- 13.4.1 COMPANY OVERVIEW
- 13.4.2 FINANCIAL OVERVIEW
- 13.4.3 PRODUCTS OFFERED
- 13.4.4 KEY DEVELOPMENTS
- 13.4.5 KEY STRATEGIES
13.5 CIPLA INC
- 13.5.1 COMPANY OVERVIEW
- 13.5.2 FINANCIAL OVERVIEW
- 13.5.3 PRODUCTS OFFERED
- 13.5.4 KEY DEVELOPMENTS
- 13.5.5 KEY STRATEGIES
13.6 NOVARTIS AG
- 13.6.1 COMPANY OVERVIEW
- 13.6.2 FINANCIAL OVERVIEW
- 13.6.3 PRODUCTS OFFERED
- 13.6.4 KEY DEVELOPMENTS
- 13.6.5 SWOT ANALYSIS
- 13.6.6 KEY STRATEGIES
13.7 SANOFI S.A.
- 13.7.1 COMPANY OVERVIEW
- 13.7.2 FINANCIAL OVERVIEW
- 13.7.3 PRODUCTS OFFERED
- 13.7.4 KEY DEVELOPMENTS
- 13.7.5 SWOT ANALYSIS
- 13.7.6 KEY STRATEGIES
13.8 ABBOTT
- 13.8.1 COMPANY OVERVIEW
- 13.8.2 FINANCIAL OVERVIEW
- 13.8.3 PRODUCTS OFFERED
- 13.8.4 KEY DEVELOPMENTS
- 13.8.5 KEY STRATEGIES
13.9 JOHNSON & JOHNSON SERVICES, INC
- 13.9.1 COMPANY OVERVIEW
- 13.9.2 FINANCIAL OVERVIEW
- 13.9.3 PRODUCTS OFFERED
- 13.9.4 KEY DEVELOPMENTS
- 13.9.5 SWOT ANALYSIS
- 13.9.6 KEY STRATEGIES
13.10 GLAXOSMITHKLINE PLC
- 13.10.1 COMPANY OVERVIEW
- 13.10.2 FINANCIAL OVERVIEW
- 13.10.3 PRODUCTS OFFERED
- 13.10.4 KEY DEVELOPMENTS
- 13.10.5 KEY STRATEGIES

14 APPENDIX

14.1 REFERENCES
14.2 RELATED REPORTS

簡介目錄圖表

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR AZOLES, BY REGION 2019-2032 (USD BILLION)
TABLE 5 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ECHINOCANDINS, BY REGION 2019-2032 (USD BILLION)
TABLE 6 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR POLYENES, BY REGION 2019-2032 (USD BILLION)
TABLE 7 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ALLYLAMINES, BY REGION 2019-2032 (USD BILLION)
TABLE 8 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR PYRIMIDINES, BY REGION 2019-2032 (USD BILLION)
TABLE 9 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR OTHERS, BY REGION 2019-2032 (USD BILLION)
TABLE 10 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 11 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ORAL, BY REGION 2019-2032 (USD BILLION)
TABLE 12 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR TOPICAL, BY REGION 2019-2032 (USD BILLION)
TABLE 13 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR PARENTERAL, BY REGION 2019-2032(USD BILLION)
TABLE 14 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY INDICATION, 2019-2032(USD BILLION)
TABLE 15 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR DERMATOPHYTOSIS, BY REGION 2019-2032 (USD BILLION)
TABLE 16 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY REGION 2019-2032 (USD BILLION)
TABLE 17 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY REGION 2019-2032 (USD BILLION)
TABLE 18 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR INVASIVE CANDIDIASIS, BY REGION 2019-2032 (USD BILLION)
TABLE 19 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR VULVOVAGINAL CANDIDIASIS, BY REGION 2019-2032 (USD BILLION)
TABLE 20 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR MOUTH/THROAT/ESOPHAGEAL CANDIDIASIS, BY REGION 2019-2032 (USD BILLION)
TABLE 21 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR OTHERS, BY REGION 2019-2032 (USD BILLION)
TABLE 22 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY PATHOGENS, 2019-2032 (USD BILLION)
TABLE 23 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR CANDIDA, BY REGION 2019-2032 (USD BILLION)
TABLE 24 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ASPERGILLUS, BY REGION 2019-2032 (USD BILLION)
TABLE 25 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR CRYPTOCOCCUS, BY REGION 2019-2032 (USD BILLION)
TABLE 26 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY REGION 2019-2032 (USD BILLION)
TABLE 27 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ZYGOMYCETES, BY REGION 2019-2032 (USD BILLION)
TABLE 28 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR TRICHOPHYTON, BY REGION 2019-2032 (USD BILLION)
TABLE 29 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR OTHERS, BY REGION 2019-2032 (USD BILLION)
TABLE 30 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 31 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR HOSPITALS AND CLINICS, BY REGION 2019-2032 (USD BILLION)
TABLE 32 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR DERMATOLOGICAL CLINICS, BY REGION 2019-2032(USD BILLION)
TABLE 33 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR OTHERS, BY REGION 2019-2032 (USD BILLION)
TABLE 34 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY REGION, 2019-2032(USD BILLION)
TABLE 35 NUMBER OF DEATHS FROM FUNGAL INFECTIONS IN THE US DURING 2019-2021
TABLE 36 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY COUNTRY, 2019-2032(USD BILLION)
TABLE 37 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032(USD BILLION)
TABLE 38 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019-2032(USD BILLION)
TABLE 39 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019-2032(USD BILLION)
TABLE 40 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019-2032(USD BILLION)
TABLE 41 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019-2032(USD BILLION)
TABLE 42 US: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032(USD BILLION)
TABLE 43 US: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019-2032(USD BILLION)
TABLE 44 US: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019-2032(USD BILLION)
TABLE 45 US: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019-2032(USD BILLION)
TABLE 46 US: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019-2032(USD BILLION)
TABLE 47 CANADA: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032(USD BILLION)
TABLE 48 CANADA: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019-2032(USD BILLION)
TABLE 49 CANADA: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019-2032(USD BILLION)
TABLE 50 CANADA: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019-2032(USD BILLION)
TABLE 51 CANADA: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019-2032(USD BILLION)
TABLE 52 EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY COUNTRY, 2019-2032(USD BILLION)
TABLE 53 EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 54 EUROPE: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019-2032(USD BILLION)
TABLE 55 EUROPE: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019-2032(USD BILLION)
TABLE 56 EUROPE: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019-2032(USD BILLION)
TABLE 57 EUROPE: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019-2032(USD BILLION)
TABLE 58 GERMANY: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032(USD BILLION)
TABLE 59 GERMANY: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019-2032(USD BILLION)
TABLE 60 GERMANY: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019-2032(USD BILLION)
TABLE 61 GERMANY ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019-2032(USD BILLION)
TABLE 62 GERMANY: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019-2032(USD BILLION)
TABLE 63 FRANCE: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032(USD BILLION)
TABLE 64 FRANCE: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019-2032(USD BILLION)
TABLE 65 FRANCE: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019-2032(USD BILLION)
TABLE 66 FRANCE: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019-2032(USD BILLION)
TABLE 67 FRANCE: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019-2032(USD BILLION)
TABLE 68 UK: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032(USD BILLION)
TABLE 69 UK: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019-2032(USD BILLION)
TABLE 70 UK: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019-2032(USD BILLION)
TABLE 71 UK: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019-2032(USD BILLION)
TABLE 72 UK: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019-2032(USD BILLION)
TABLE 73 ITALY: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032(USD BILLION)
TABLE 74 ITALY: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019-2032(USD BILLION)
TABLE 75 ITALY: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019-2032(USD BILLION)
TABLE 76 ITALY: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019-2032(USD BILLION)
TABLE 77 ITALY: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019-2032(USD BILLION)
TABLE 78 SPAIN: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032(USD BILLION)
TABLE 79 SPAIN: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019-2032(USD BILLION)
TABLE 80 SPAIN: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019-2032(USD BILLION)
TABLE 81 SPAIN: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019-2032(USD BILLION)
TABLE 82 SPAIN: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019-2032(USD BILLION)
TABLE 83 SWITZERLAND: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032(USD BILLION)
TABLE 84 SWITZERLAND: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019-2032(USD BILLION)
TABLE 85 SWITZERLAND: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019-2032(USD BILLION)
TABLE 86 SWITZERLAND: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019-2032(USD BILLION)
TABLE 87 SWITZERLAND: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019-2032(USD BILLION)
TABLE 88 REST OF EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032(USD BILLION)
TABLE 89 REST OF EUROPE: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019-2032(USD BILLION)
TABLE 90 REST OF EUROPE: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019-2032(USD BILLION)
TABLE 91 REST OF EUROPE: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019-2032(USD BILLION)
TABLE 92 REST OF EUROPE: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019-2032(USD BILLION)
TABLE 93 ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 94 ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 95 ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 96 ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 97 ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019-2032 (USD BILLION)
TABLE 98 ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 99 CHINA ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 100 CHINA ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 101 CHINA ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 102 CHINA ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019-2032 (USD BILLION)
TABLE 103 CHINA ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 104 INDIA ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 105 INDIA ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 106 INDIA ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 107 INDIA ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019-2032 (USD BILLION)
TABLE 108 INDIA ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 109 JAPAN ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 110 JAPAN ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 111 JAPAN ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 112 JAPAN ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019-2032 (USD BILLION)
TABLE 113 JAPAN ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 114 SOUTH KOREA ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 115 SOUTH KOREA ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 116 SOUTH KOREA ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 117 SOUTH KOREA ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019-2032 (USD BILLION)
TABLE 118 SOUTH KOREA ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 119 AUSTRALIA ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 120 AUSTRALIA ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 121 AUSTRALIA ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 122 AUSTRALIA ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019-2032 (USD BILLION)
TABLE 123 AUSTRALIA ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 124 REST OF ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 125 REST OF ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 126 REST OF ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 127 REST OF ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019-2032 (USD BILLION)
TABLE 128 REST OF ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 129 REST OF THE WORLD ANTI-FUNGAL TREATMENT MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 130 REST OF THE WORLD ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 131 REST OF THE WORLD ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 132 REST OF THE WORLD ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 133 REST OF THE WORLD ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019-2032 (USD BILLION)
TABLE 134 REST OF THE WORLD ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 135 MIDDLE EAST ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 136 MIDDLE EAST ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 137 MIDDLE EAST ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 138 MIDDLE EAST ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019-2032 (USD BILLION)
TABLE 139 MIDDLE EAST ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 140 AFRICA ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 141 AFRICA ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 142 AFRICA ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 143 AFRICA ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019-2032 (USD BILLION)
TABLE 144 AFRICA ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 145 LATIN AMERICA ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 146 LATIN AMERICA ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 147 LATIN AMERICA ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
TABLE 148 LATIN AMERICA ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019-2032 (USD BILLION)
TABLE 149 LATIN AMERICA ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019-2032 (USD BILLION)
TABLE 150 MAJOR PLAYERS IN THE ANTI-FUNGAL TREATMENT MARKET
TABLE 151 MOST ACTIVE PLAYER IN THE ANTI-FUNGAL TREATMENT MARKET
TABLE 152 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 153 ACQUISITION
TABLE 154 AGREEMENT
TABLE 155 PARTNERSHIP
TABLE 156 EXPANSION
TABLE 157 PFIZER INC: PRODUCTS OFFERED
TABLE 158 PFIZER INC: KEY DEVELOPMENTS
TABLE 159 MERCK KGAA: PRODUCTS OFFERED
TABLE 160 GILEAD SCIENCES, INC: PRODUCTS OFFERED
TABLE 161 SBAYER AG: PRODUCTS OFFERED
TABLE 162 BAYER AG: KEY DEVELOPMENTS
TABLE 163 CIPLA INC: PRODUCTS OFFERED
TABLE 164 CIPLA INC: KEY DEVELOPMENTS
TABLE 165 NOVARTIS AG: PRODUCTS OFFERED
TABLE 166 SANOFI S.A.: PRODUCTS OFFERED
TABLE 167 ABBOTT: PRODUCTS OFFERED
TABLE 168 JOHNSON & JOHNSON SERVICES, INC: PRODUCTS OFFERED
TABLE 169 GLAXOSMITH KLINE PLC: PRODUCTS OFFERED
TABLE 170 GLAXOSMITH KLINE PLC: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS
FIGURE 2 GLOBAL ANTI-FUNGAL TREATMENT MARKET
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS OVERVIEW
FIGURE 5 DRIVER IMPACT ANALYSIS
FIGURE 6 RESTRAINT IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL ANTI-FUNGAL TREATMENT MARKET
FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL ANTI-FUNGAL TREATMENT MARKET
FIGURE 9 GLOBAL ANTIFUNGAL TREATMENT MARKET, DRUG CLASS SEGMENT ATTRACTIVENESS, 2022 & 2032 (USD BILLION)
FIGURE 10 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY DRUG CLASS, 2022 & 2032 (USD BILLION)
FIGURE 11 GLOBAL ANTIFUNGAL TREATMENT MARKET SHARE, BY DRUG CLASS, 2022 (%)
FIGURE 12 GLOBAL ANTIFUNGAL TREATMENT MARKET, ROUTE OF ADMINISTRATION SEGMENT ATTRACTIVENESS, 2022 & 2032 (USD BILLION)
FIGURE 13 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022 & 2032 (USD BILLION)
FIGURE 14 GLOBAL ANTIFUNGAL TREATMENT MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2022 (%)
FIGURE 15 GLOBAL ANTIFUNGAL TREATMENT MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2022 & 2032 (USD BILLION)
FIGURE 16 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY INDICATION, 2022 & 2032 (USD BILLION)
FIGURE 17 GLOBAL ANTIFUNGAL TREATMENT MARKET SHARE, BY INDICATION, 2022 (%)
FIGURE 18 GLOBAL ANTIFUNGAL TREATMENT MARKET, PATHOGENS SEGMENT ATTRACTIVENESS, 2022 & 2032 (USD BILLION)
FIGURE 19 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY PATHOGENS, 2022 & 2032 (USD BILLION)
FIGURE 20 GLOBAL ANTIFUNGAL TREATMENT MARKET SHARE, BY PATHOGENS, 2022 (%)
FIGURE 21 GLOBAL ANTIFUNGAL TREATMENT MARKET, END USER SEGMENT ATTRACTIVENESS, 2022 & 2032 (USD BILLION)
FIGURE 22 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY END USER, 2022 & 2032 (USD BILLION)
FIGURE 23 GLOBAL ANTIFUNGAL TREATMENT MARKET SHARE, BY END USER, 2022 (%)
FIGURE 24 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY REGION, 2022 & 2030 (USD BILLION)
FIGURE 25 GLOBAL: ANTI-FUNGAL TREATMENT MARKET SHARE (%), BY REGION, 2022
FIGURE 26 NORTH AMERICA MARKET ANALYSIS: ANTI-FUNGAL TREATMENT MARKET, 2019-2032 (USD BILLION)
FIGURE 27 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY REGION, 2022 & 2030 (USD BILLION)
FIGURE 28 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 29 EUROPE MARKET ANALYSIS: ANTI-FUNGAL TREATMENT MARKET, 2019-2032 (USD BILLION)
FIGURE 30 EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY COUNTRY, 2022 & 2030 (USD BILLION)
FIGURE 31 EUROPE: ANTI-FUNGAL TREATMENT MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 32 ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)
FIGURE 33 ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET SHARE, BY COUNTRY, 2022 (%)
FIGURE 34 ASIA-PACIFIC MARKET ANALYSIS: ANTI-FUNGAL TREATMENT MARKET, 2019-2032 (USD BILLION)
FIGURE 35 REST OF THE WORLD ANTI-FUNGAL TREATMENT MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)
FIGURE 36 REST OF THE WORLD ANTI-FUNGAL TREATMENT MARKET SHARE, BY COUNTRY, 2022 (%)
FIGURE 37 REST OF THE WORLD MARKET ANALYSIS: ANTI-FUNGAL TREATMENT MARKET, 2019-2032 (USD BILLION)
FIGURE 38 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 39 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE ANTI-FUNGAL TREATMENT MARKET
FIGURE 40 ANTI-FUNGAL TREATMENT MARKET: COMPETITIVE LANDSCAPE
FIGURE 41 MAJOR PLAYERS SALES (USD BILLION), 2022
FIGURE 42 MAJOR PLAYER R&D EXPENDITURE (USD BILLION), 2022
FIGURE 43 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 44 PFIZER INC: SWOT ANALYSIS
FIGURE 45 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 46 MERCK KGAA: SWOT ANALYSIS
FIGURE 47 GILEAD SCIENCES, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 48 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 49 CIPLA INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 50 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 51 NOVARTIS AG: SWOT ANALYSIS
FIGURE 52 SANOFI S.A.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 53 SANOFI S.A.: SWOT ANALYSIS
FIGURE 54 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 55 JOHNSON & JOHNSON SERVICES, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 56 JOHNSON & JOHNSON SERVICES, INC: SWOT ANALYSIS
FIGURE 57 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT